Skip to main content
Top
Published in: Endocrine 3/2012

01-12-2012 | Original Article

Mutations in the AVPR2, AVP-NPII, and AQP2 genes in Turkish patients with diabetes insipidus

Authors: Duygu Duzenli, Emel Saglar, Ferhat Deniz, Omer Azal, Beril Erdem, Hatice Mergen

Published in: Endocrine | Issue 3/2012

Login to get access

Abstract

The aim of this study was to identify mutations in three different genes, the arginine-vasopressin-neurophysin II (AVP-NPII) gene, the arginine-vasopressin receptor 2 (AVPR2) gene, and the vasopressin-sensitive water channel aquaporin-2 (AQP2) gene in Turkish patients affected by central diabetes insipidus or nephrogenic diabetes insipidus. This study included 15 patients from unrelated families. Prospective clinical data were collected for all patients including the patients underwent a water deprivation–desmopressin test. The coding regions of the AVPR2, AQP2, and AVP-NPII genes were amplified by polymerase chain reaction and submitted to direct sequence analysis. Of the 15 patients with diabetes insipidus referred to Gulhane Military Medical Academy, Department of Endocrinology and Metabolism, eight patients have AVPR2 mutations, five patients have AQP2 mutations and two patients have AVP-NPII mutations. Of the patients, which have AVPR2 mutations, one is compound heterozygous for AVPR2 gene. Seven of these mutations are novel. Comparison of the clinical outcomes of these mutations may facilitate in understanding the functions of AVP-NPII, AQP2, and AVPR2 genes in future studies.
Literature
1.
go back to reference A.N. Makaryus, S.I. McFarlane, Diabetes insipidus: diagnosis and treatment of a complex disease. Clevel. Clin. J. Med. 73(1), 65–71 (2006)CrossRef A.N. Makaryus, S.I. McFarlane, Diabetes insipidus: diagnosis and treatment of a complex disease. Clevel. Clin. J. Med. 73(1), 65–71 (2006)CrossRef
2.
go back to reference J.A. Majzoub, A. Srivatsa, Diabetes insipidus: clinical and basic aspects. Pediatr. Endocrinol. Rev. 4(Suppl 1), 60–65 (2006)PubMed J.A. Majzoub, A. Srivatsa, Diabetes insipidus: clinical and basic aspects. Pediatr. Endocrinol. Rev. 4(Suppl 1), 60–65 (2006)PubMed
3.
go back to reference S.A. Ranadive, B. Ersoy, H. Favre, C.C. Cheung, S.M. Rosenthal, W.L. Miller, C. Vaisse, Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus. Clin. Endocrinol. (Oxf) 71(3), 388–393 (2009)CrossRef S.A. Ranadive, B. Ersoy, H. Favre, C.C. Cheung, S.M. Rosenthal, W.L. Miller, C. Vaisse, Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus. Clin. Endocrinol. (Oxf) 71(3), 388–393 (2009)CrossRef
4.
go back to reference T.M. Fujiwara, D.G. Bichet, Molecular biology of hereditary diabetes insipidus. J. Am. Soc. Nephrol. 16, 2836–2846 (2005)PubMedCrossRef T.M. Fujiwara, D.G. Bichet, Molecular biology of hereditary diabetes insipidus. J. Am. Soc. Nephrol. 16, 2836–2846 (2005)PubMedCrossRef
5.
go back to reference P.W. Oakley, I.M. Whyte, G.L. Carter, Lithium toxicity: an iatrogenic problem in susceptible individuals. Aust. N. Z. J. Psychiatry 35(6), 833–840 (2001)PubMedCrossRef P.W. Oakley, I.M. Whyte, G.L. Carter, Lithium toxicity: an iatrogenic problem in susceptible individuals. Aust. N. Z. J. Psychiatry 35(6), 833–840 (2001)PubMedCrossRef
6.
go back to reference N.V.A.M. Knoers, P.M.T. Deen, Molecular and cellular defects in nephrogenic diabetes insipidus. Pediatr. Nephrol. 16, 1146–1152 (2001)PubMedCrossRef N.V.A.M. Knoers, P.M.T. Deen, Molecular and cellular defects in nephrogenic diabetes insipidus. Pediatr. Nephrol. 16, 1146–1152 (2001)PubMedCrossRef
7.
go back to reference H. Mizuno, Y. Sugiyama, Y. Ohro, H. Imamine, M. Kobayashi, S. Sasaki, S. Uchida, H. Togari, Clinical characteristics of eight patients with congenital nephrogenic diabetes insipidus. Endocrine 24(1), 55–59 (2004)PubMedCrossRef H. Mizuno, Y. Sugiyama, Y. Ohro, H. Imamine, M. Kobayashi, S. Sasaki, S. Uchida, H. Togari, Clinical characteristics of eight patients with congenital nephrogenic diabetes insipidus. Endocrine 24(1), 55–59 (2004)PubMedCrossRef
8.
go back to reference D.G. Bichet, V2R mutations and nephrogenic diabetes insipidus. Prog. Mol. Biol. Transl. Sci. 89, 15–29 (2009)PubMedCrossRef D.G. Bichet, V2R mutations and nephrogenic diabetes insipidus. Prog. Mol. Biol. Transl. Sci. 89, 15–29 (2009)PubMedCrossRef
9.
go back to reference B.R. Migeon, X inactivation, female mosaicism, and sex differences in renal diseases. J. Am. Soc. Nephrol. 19(11), 2052–2059 (2008)PubMedCrossRef B.R. Migeon, X inactivation, female mosaicism, and sex differences in renal diseases. J. Am. Soc. Nephrol. 19(11), 2052–2059 (2008)PubMedCrossRef
10.
go back to reference S.M. Mulders, N.V. Knoers, A.F. Van Lieburg, L.A. Monnens, E. Leumann, E. Wühl, E. Schober, J.P. Rijss, C.H. Van Os, P.M. Deen, New mutations in the AQP2 gene in nephrogenic diabetes insipidus resulting in functional but misrouted water channels. J. Am. Soc. Nephrol. 8(2), 242–248 (1997)PubMed S.M. Mulders, N.V. Knoers, A.F. Van Lieburg, L.A. Monnens, E. Leumann, E. Wühl, E. Schober, J.P. Rijss, C.H. Van Os, P.M. Deen, New mutations in the AQP2 gene in nephrogenic diabetes insipidus resulting in functional but misrouted water channels. J. Am. Soc. Nephrol. 8(2), 242–248 (1997)PubMed
11.
go back to reference P. Saborio, G.A. Tipton, J.C. Chan, Diabetes insipidus. Pediatr. Rev. 21(4), 122–129 (2000). quiz 129PubMedCrossRef P. Saborio, G.A. Tipton, J.C. Chan, Diabetes insipidus. Pediatr. Rev. 21(4), 122–129 (2000). quiz 129PubMedCrossRef
12.
go back to reference E. Spanakis, E. Milord, C. Gragnoli, AVPR2 variants and mutations in nephrogenic diabetes insipidus: review and missense mutation significance. J. Cell Physiol. 217(3), 605–617 (2008)PubMedCrossRef E. Spanakis, E. Milord, C. Gragnoli, AVPR2 variants and mutations in nephrogenic diabetes insipidus: review and missense mutation significance. J. Cell Physiol. 217(3), 605–617 (2008)PubMedCrossRef
13.
go back to reference D.G. Bichet, M. Birnbaumer, M. Lonergan, M.F. Arthus, W. Rosenthal, P. Goodyer, H. Nivet, S. Benoit, P. Giampietro, S. Simonetti et al., Nature and recurrence of AVPR2 mutations in X-linked nephrogenic diabetes insipidus. Am. J. Hum. Genet. 55(2), 278–286 (1994)PubMed D.G. Bichet, M. Birnbaumer, M. Lonergan, M.F. Arthus, W. Rosenthal, P. Goodyer, H. Nivet, S. Benoit, P. Giampietro, S. Simonetti et al., Nature and recurrence of AVPR2 mutations in X-linked nephrogenic diabetes insipidus. Am. J. Hum. Genet. 55(2), 278–286 (1994)PubMed
14.
go back to reference D. Wenkert, J.J. Merendino Jr, A. Shenker, N. Thambi, G.L. Robertson, A.M. Moses, A.M. Spiegel, Novel mutations in the V2 vasopressin receptor gene of patients with X-linked nephrogenic diabetes insipidus. Hum. Mol. Genet. 3(8), 1429–1430 (1994)PubMedCrossRef D. Wenkert, J.J. Merendino Jr, A. Shenker, N. Thambi, G.L. Robertson, A.M. Moses, A.M. Spiegel, Novel mutations in the V2 vasopressin receptor gene of patients with X-linked nephrogenic diabetes insipidus. Hum. Mol. Genet. 3(8), 1429–1430 (1994)PubMedCrossRef
15.
go back to reference R. Vargas-Poussou, L. Forestier, M.D. Dautzenberg, P. Niaudet, M. Déchaux, C. Antignac, Mutations in the vasopressin V2 receptor and aquaporin-2 genes in 12 families with congenital nephrogenic diabetes insipidus. J. Am. Soc. Nephrol. 8(12), 1855–1862 (1997)PubMed R. Vargas-Poussou, L. Forestier, M.D. Dautzenberg, P. Niaudet, M. Déchaux, C. Antignac, Mutations in the vasopressin V2 receptor and aquaporin-2 genes in 12 families with congenital nephrogenic diabetes insipidus. J. Am. Soc. Nephrol. 8(12), 1855–1862 (1997)PubMed
16.
go back to reference J. Santiprabhob, J. Browning, D. Repaske, A missense mutation encoding Cys73Phe in neurophysin II is associated with autosomal dominant neurohypophyseal diabetes insipidus. Mol. Genet. Metab. 77(1–2), 112–118 (2002)PubMedCrossRef J. Santiprabhob, J. Browning, D. Repaske, A missense mutation encoding Cys73Phe in neurophysin II is associated with autosomal dominant neurohypophyseal diabetes insipidus. Mol. Genet. Metab. 77(1–2), 112–118 (2002)PubMedCrossRef
17.
go back to reference I. Böselt, D. Tramma, S. Kalamitsou, T. Niemeyer, P. Nykänen, K.J. Gräf, H. Krude, K.S. Marenzi, S. Di Candia, T. Schöneberg, A. Schulz, Functional characterization of novel loss-of-function mutations in the vasopressin type 2 receptor gene causing nephrogenic diabetes insipidus. Nephrol. Dial. Transplant. 27(4), 1521–1528 (2011)PubMedCrossRef I. Böselt, D. Tramma, S. Kalamitsou, T. Niemeyer, P. Nykänen, K.J. Gräf, H. Krude, K.S. Marenzi, S. Di Candia, T. Schöneberg, A. Schulz, Functional characterization of novel loss-of-function mutations in the vasopressin type 2 receptor gene causing nephrogenic diabetes insipidus. Nephrol. Dial. Transplant. 27(4), 1521–1528 (2011)PubMedCrossRef
18.
go back to reference C.H. Chen, W.Y. Chen, H.L. Liu, T.T. Liu, A.P. Tsou, C.Y. Lin, T. Chao, Y. Qi, K.J. Hsiao, Identification of mutations in the arginine vasopressin receptor 2 gene causing nephrogenic diabetes insipidus in Chinese patients. J. Hum. Genet. 47(2), 66–73 (2002)PubMedCrossRef C.H. Chen, W.Y. Chen, H.L. Liu, T.T. Liu, A.P. Tsou, C.Y. Lin, T. Chao, Y. Qi, K.J. Hsiao, Identification of mutations in the arginine vasopressin receptor 2 gene causing nephrogenic diabetes insipidus in Chinese patients. J. Hum. Genet. 47(2), 66–73 (2002)PubMedCrossRef
19.
go back to reference M. Fysekidis, J.J. Boffa, L. Baud, J.P. Haymann, The R106C mutation of the V2 vasopressor receptor gene (AVPR2) causing X linked congenital nephrogenic diabetes insipidus is responsive to short term desmopressin challenge. Endocr. Abstr. 20, P291 (2009) M. Fysekidis, J.J. Boffa, L. Baud, J.P. Haymann, The R106C mutation of the V2 vasopressor receptor gene (AVPR2) causing X linked congenital nephrogenic diabetes insipidus is responsive to short term desmopressin challenge. Endocr. Abstr. 20, P291 (2009)
20.
go back to reference C. Guyon, Y. Lussier, P. Bissonnette, A. Leduc-Nadeau, M. Lonergan, M.F. Arthus, R.B. Perez, A. Tiulpakov, J.Y. Lapointe, D.G. Bichet, Characterization of D150E and G196D aquaporin-2 mutations responsible for nephrogenic diabetes insipidus: importance of a mild phenotype. Am. J. Physiol. Renal. Physiol. 297(2), F489–F498 (2009)PubMedCrossRef C. Guyon, Y. Lussier, P. Bissonnette, A. Leduc-Nadeau, M. Lonergan, M.F. Arthus, R.B. Perez, A. Tiulpakov, J.Y. Lapointe, D.G. Bichet, Characterization of D150E and G196D aquaporin-2 mutations responsible for nephrogenic diabetes insipidus: importance of a mild phenotype. Am. J. Physiol. Renal. Physiol. 297(2), F489–F498 (2009)PubMedCrossRef
21.
go back to reference E.J. Kamsteeg, P.M. Deen, C.H. van Os, Defective processing and trafficking of water channels in nephrogenic diabetes insipidus. Exp. Nephrol. 8, 326–331 (2000)PubMedCrossRef E.J. Kamsteeg, P.M. Deen, C.H. van Os, Defective processing and trafficking of water channels in nephrogenic diabetes insipidus. Exp. Nephrol. 8, 326–331 (2000)PubMedCrossRef
22.
go back to reference J. Davies, D. Murphy, Autophagy in hypothalamic neurones of rats expressing a familial neurohypophysial diabetes insipidus transgene. J. Neuroendocrinol. 14, 629–637 (2002)PubMedCrossRef J. Davies, D. Murphy, Autophagy in hypothalamic neurones of rats expressing a familial neurohypophysial diabetes insipidus transgene. J. Neuroendocrinol. 14, 629–637 (2002)PubMedCrossRef
23.
go back to reference C.M. Hedrich, A.Z. Buczynska, A. Gawlil, S. Russ, G. Hahn, K. Koehler, E.M. Tendera, A. Huebner, Autosomal neurohypophyseal diabetes insipidus in two families. Horm. Res. 71, 111–119 (2009)PubMedCrossRef C.M. Hedrich, A.Z. Buczynska, A. Gawlil, S. Russ, G. Hahn, K. Koehler, E.M. Tendera, A. Huebner, Autosomal neurohypophyseal diabetes insipidus in two families. Horm. Res. 71, 111–119 (2009)PubMedCrossRef
24.
go back to reference S. Rittig, C. Siggaard, M. Ozata, I. Yetkin, N. Gregersen, E.B. Pedersen, G.L. Robertson, Autosomal dominant neurohypophyseal diabetes insipidus due to substitution of histidine for tyrosine-2 in the vasopressin moiety of the hormone precursor. J. Clin. Endocrinol. Metab. 87, 3351–3355 (2002)PubMedCrossRef S. Rittig, C. Siggaard, M. Ozata, I. Yetkin, N. Gregersen, E.B. Pedersen, G.L. Robertson, Autosomal dominant neurohypophyseal diabetes insipidus due to substitution of histidine for tyrosine-2 in the vasopressin moiety of the hormone precursor. J. Clin. Endocrinol. Metab. 87, 3351–3355 (2002)PubMedCrossRef
25.
go back to reference J.H. Christensen, C. Siggaard, S. Rittig, Autosomal dominant familial neurohypophyseal diabetes insipidus. APMIS 109, 92–95 (2003) J.H. Christensen, C. Siggaard, S. Rittig, Autosomal dominant familial neurohypophyseal diabetes insipidus. APMIS 109, 92–95 (2003)
26.
go back to reference M. Ito, Y. Mori, Y. Oiso, H. Saito, A single base substitution in the coding region for neurophysin II associated with familial central diabetes insipidus. J Clin. Invest. 87(2), 725–728 (1991)PubMedCrossRef M. Ito, Y. Mori, Y. Oiso, H. Saito, A single base substitution in the coding region for neurophysin II associated with familial central diabetes insipidus. J Clin. Invest. 87(2), 725–728 (1991)PubMedCrossRef
27.
Metadata
Title
Mutations in the AVPR2, AVP-NPII, and AQP2 genes in Turkish patients with diabetes insipidus
Authors
Duygu Duzenli
Emel Saglar
Ferhat Deniz
Omer Azal
Beril Erdem
Hatice Mergen
Publication date
01-12-2012
Publisher
Springer US
Published in
Endocrine / Issue 3/2012
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-012-9704-1

Other articles of this Issue 3/2012

Endocrine 3/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.